Myosin Therapeutics Invited To Present at Biocom California’s Global Partnering & Investor Conference (PR Newswire)
UF startup Myosin Therapeutics has been selected to present at Biocom California’s Global Partnering & Investor Conference. Company leadership will share progress and engage with investors and strategic partners, highlighting continued momentum in advancing its therapeutic pipeline.
LightPath Technologies Acquires Amorphous Materials, Inc. (PR Newswire)
UF startup LightPath Technologies, Inc. announced it has acquired the assets of Amorphous Materials, Inc., which is an industrial manufacturer with complementary Chalcogenide glass melting technologies.
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership (PR Newswire)
UF startup Atsena Therapeutics and Genezen announced a manufacturing partnership to support the clinical development and future production of Atsena’s gene therapies for inherited retinal diseases.
Neuropacs Closes Seed Round of Financing (Businesswire)
UF startup neuropacs™ Corp. announced the successful raise of over $1.0 million in early-stage capital.
Solid Biosciences Doses First Patient in Phase 1b FALCON Trial for Friedreich’s Ataxia (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for the treatment of Friedreich’s ataxia (FA).
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (Bio Space)
Solid Biosciences Inc., which acquired UF startup AavantiBio, shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the list of conditions recommended for universal newborn screening across the United States.
TuHURA Biosciences Announces Its Release of Kintara’s Contingent Value Right (CVR) As Kintara’s REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone (PR Newswire))
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that Kintara’s REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its primary endpoint, demonstrating safety with signs of clinical efficacy following eight weeks of follow-up for such patients.
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (Globe Newswire)
UF startup Axogen, Inc., announced that the U.S. Food and Drug Administration has approved the Biologics License Application for AVANCE® (acellular nerve allograft-arwx).
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s investigational gene therapy for Friedreich’s ataxia (FA).
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PR Newswire)
UF startup Dialectic Therapeutics has begun patient dosing in a clinical trial of its novel therapy for platinum-resistant ovarian cancer, marking a key milestone in its progress toward new treatment options.